ASCT May Offer Alternative for Tx of High-Risk Follicular Lymphoma
THURSDAY, July 25, 2019 -- Autologous stem cell transplantation (ASCT) may be an effective treatment option in high-risk, early therapy failure (ETF) follicular lymphoma (FL), prior to the use of rituximab, according to a study published online July...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Lymphoma | Pharmaceuticals | Rituxan | Stem Cell Therapy | Stem Cells | Study | Transplants